Results of simulation of performance indicators for the oncological service when introducing innovative technologies for treatment of stage IV lung cancer
https://doi.org/10.21292/2075-1230-2020-98-4-15-23
Abstract
Malignant tumors of the trachea, bronchi, lungs represent a serious medical and social problem. Most cases of cancer of the trachea, bronchus, and lung are detected at stage IV, and therefore, to improve the survival of patients, a new treatment strategy is proposed based on modern data on mutagenesis and receptor status of tumor cells, which has a personalized approach for each specific case. To make managerial decisions about the introduction of innovative drugs, a forecast of expected results is required which should be improved indicators of the State Program On Healthcare Development. It has been found out that the transition to a new strategy for lung cancer chemotherapy will reduce mortality from malignant tumors by 1.2-0.7%, including lung cancer by 3.9%, as well as one-year case fatality by 3% for all malignant tumors, including 15% for lung cancer. At the same time, within 5 years after the introduction of the new strategy for lung cancer treatment, the indicator reflecting the proportion of patients with malignant tumors registered for 5 years or more is expected to decrease, which is related to specific parameters of the calculation method.
The authors state that they have no conflict of interests.
About the Authors
S. A. Sterlikov
Federal Research Institute for Health Organization and Informatics by the Russian Ministry of Health
Russian Federation
Russian Federation
Sergey A. Sterlikov Doctor of Medical Sciences, Deputy Head of Federal Monitoring Center for Prevention of Tuberculosis Transmission in the Russian Federation within Program Monitoring.
Phone/Fax: +7 (925) 507-82-21, +7 (495) 618-22-10
O. V. Zelenova
Federal Research Institute for Health Organization and Informatics by the Russian Ministry of Health
Russian Federation
Russian Federation
Olga V. Zelenova Doctor of Medical Sciences, Head of Department for Clinical and Economic Assessment of Medical Healthcare Technologies.
Phone/Fax: +7 (495) 618-22-10.
S. I. Аbramov
Federal Research Institute for Health Organization and Informatics by the Russian Ministry of Health
Russian Federation
Russian Federation
Sergey I. Аbramov Chief Specialist of Medical Statistics Department.
Phone/Fax: +7 (495) 618-22-10
V. M. Danilov
Voronezh State Medical University named after N. N. Burdenko
Russian Federation
Russian Federation
Valery M. Danilov The Institute of Advanced Training
Post Graduate Student of Oncology and Specialized Surgery Departmen
Phone/Fax: +7 (473) 255-57-53.
Yu. V. Mikhaylova
Federal Research Institute for Health Organization and Informatics by the Russian Ministry of Health
Russian Federation
Russian Federation
Yulia V. Mikhaylova Doctor of Medical Sciences, Professor, First Deputy Director.
Phone/Fax: +7 (495) 618-32-68
N. A. Golubev
Federal Research Institute for Health Organization and Informatics by the Russian Ministry of Health
Russian Federation
Russian Federation
Nikita A. Golubev Candidate of Medical Sciences, Head of Statistics Department, Head of Medical Department.
Phone/Fax: +7 (495) 611-53-56
References
1. Kaprin А.D., Starinskiy V.V., Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2017 g.(zabolevaemost i smertnost). [Malicious tumors in Russia in 2017. (Incidence and mortality)]. Moscow, FGBU MNIOI Im. P.А. Gertsena Minzdrava RF Publ., 2018, 250 p.
2. Kaprin А.D., Starinskiy V.V., Petrova G.V. Sostoyanie onkologicheskoj pomoschi naseleniyu Rossii v 2017 g. [The state of anti-cancer care for the population of Russia in 2017]. Moscow, FGBU MNIOI Im. P.А. Gertsena Minzdrava RF Publ., 2018, 236 p.
3. On approval of the State Program of the Russian Federation On Healthcare Development. Edict no. 1640 by the RF Government as of December 26, 2017. (Epub.), Available: http://gov.garant.ru/SESSION/PILOT/main.htm (Accessed: 20.02.2019). (In Russ.)
4. Petrova G.V., Gretsova O.P., Kaprin А.D., Starinskiy V.V. Kharakteristika i metody rascheta mediko-statisticheskikh pokazateley v onkologii: Metodicheskie rekomendatsii. [Parameters and methods of calculation of medical statistical indices in oncology: guidelines]. Moscow, FGBU MNIOI Im. P.А. Gertsena Minzdrava RF Publ., 2014, 41 p.
5. Camidge R.D. Treating Patients with advanced ALK + NSCLC: What don’t we know? (Epub.), Available: http://www.hkiof.org/pdf/Satellite%20Symposium_%20Ross%20CAMIDGE.pdf (Accessed: 30.01.2018).
6. Fehrenbacher L., Pawel J., Park K., Rittmeyer A., Gandara D.R., Aix S.P., Han J., Gadgeel S.M., Hida T., Cortinovis D.L., Cobo M., Kowalski D.M., Marinis F., Gandhi M., Danner B., Matheny C., Kowanetz M., He P., Felizzi F., Patel H., Sandler A., Ballinger M., Barlesi F. Updated efficacy analysis including secondary population results for OAK: A randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer. J. Thoracic Oncology, 2018, vol. 13, no. 8, pp. 1156-1170.
7. Mok T., Socinski M.A., Reck M., Jotta R., Lim D.W., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N., Rodriguez-Abreu D., Moro-Sibilot D., Thonas C.A., Barlesi F., Finley G., Lee A., Shankar G., Yu W., Kowanetz M., Lin W., Nishio M. IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations. (Epub.), Available: https://medically.roche.com/content/dam/pdmahub/non-restricted/oncology/esmo-asia-2018/ESMO_Asia_2018_IMpower150_EGFR_Atezolizumab_Oral.pdf (Accessed: 30.01.2018).
8. Schiller J.H., Harrington D., Chandra P.B., Langer C., Sandler A., Krook J., Zhu J., Jhonson D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med., 2002, vol. 346, pp. 92-98.
9. Socinski M.A., Jotte R., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N., Rodriguez-Abreu D., Moro-Sibilot D., Thonas C.A., Barlesi F., Finley G., Kelsch C., Lee A., Coleman S., Shen Y., Kowanetz M., Lopez-Chavez A., Sandler A., Reck M. IMpower150: Overall survival analysis of a randomized phase III study of Atezolizumab + Chemotherapy ± Bevacizumab vs Chemotherapy + Bevacizumab in 1L Nonsquamous NSCLC. (Epub.), Available: https://medically.roche.com/en/search/slideviewer.a61909f7-ca3f-420e-810f-0e04410c5aa0.html (Accessed: 30.01.2018).
10. Socinski M.A., Jotte R., Cappuzzo F., Orlandi F., Stroyakovsky D., Nogami N., Rodriguez-Abreu D., Moro-Sibilot D., Thonas C. A., Barlesi F., Finley G., Kelsch C., Lee A., Coleman S., Shen Y., Kowanetz M., Lopez-Chavez A., Sandler A., Reck M. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of Atezolizumab (Atezo) + Chemotherapy (Chemo) ± Bevacizumab (Bev) vs Chemo + Bev in 1L nonsquamous (NSQ) NSCLC. J. Clin. Oncol., vol. 36, 2018 (suppl; abstr 9002).
Review
For citations:
Sterlikov S.A., Zelenova O.V., Аbramov S.I., Danilov V.M., Mikhaylova Yu.V., Golubev N.A. Results of simulation of performance indicators for the oncological service when introducing innovative technologies for treatment of stage IV lung cancer. Tuberculosis and Lung Diseases. 2020;98(4):15-23. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-4-15-23
Views:
827
Email this article 